Skip to main content
Top

Annals of Hematology

Issue 2/2000

Content (10 Articles)

ORIGINAL ARTICLE

Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases

J. Dervenoulas, P. Tsirigotis, G. Bollas, V. Pappa, N. Xiros, T. Economopoulos, M. Pappa, S. Mellou, A. Kostourou, E. Papageorgiou, S. A. Raptis

ORIGINAL ARTICLE

How to restrict liver biopsy to high-risk patients in early-stage Hodgkin's disease

D. Lieberz, M. Sextro, U. Paulus, J. Franklin, H. Tesch, V. Diehl

ORIGINAL ARTICLE

Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients

A. P. Anselmo, G. Meloni, E. Cavalieri, A. Proia, R. Maurizi Enrici, D. Funaro, E. Pescarmona, F. Mandelli

RAPID COMMUNICATION

Ceramide stimulates the uptake of neutral red in human neutrophils, monocytes, and lymphocytes

S. Sipka, P. Antal-Szalmás, I. Szöllösi, I. Csipö, G. Lakos, G. Szegedi

CASE REPORT

Bilateral breast MALT lymphoma: a case report and review of the literature

S. Gopal, S. Awasthi, M. T. Elghetany

CASE REPORT

Transient eosinophilia by HIV infection

Y. Maeda, J. Miyatake, Y. Naiki, H. Nawata, Y. Sumimoto, H. Sono, M. Sakaguchi, M. Matsuda, A. Kanamaru

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine